dr. west on fda approval of frontline alectinib in alk nsclc
Published 7 years ago • 121 plays • Length 0:55Download video MP4
Download video MP3
Similar videos
-
2:35
dr. west on fda approval of brigatinib in alk nsclc
-
5:31
fda approval: frontline ceritinib for alk nsclc
-
1:47
dr. west on fda approval of afatinib in nsclc with rare egfr mutations
-
1:42
dr. velcheti on potential of alectinib in frontline alk-positive nsclc
-
4:37
fda approval of brigatinib for alk nsclc
-
6:51
progression in alk nsclc after frontline therapy
-
1:27
dr. neal debates whether alectinib will become the standard frontline thera for alk nsclc
-
3:04
management of frontline alk nsclc: brigatinib vs. alectinib
-
0:41
dr. gandhi discusses the role of alectinib in alk lung cancer
-
0:52
dr. stinchcombe on the benefit of alectinib in alk nsclc
-
3:59
alectinib in alk-mutated nsclc
-
0:56
nautika1: safety and tolerability of neoadjuvant alectinib in alk-positive nsclc
-
1:15
dr. spigel on fda approval of pembrolizumab/chemo combo in nsclc
-
6:41
next-generation alk inhibitors for nsclc
-
1:55
dr. villaflor discusses alectinib in alk nsclc
-
2:00
updated data from phase 2 study of alectinib in alk–positive non–small–cell lung cancer
-
7:13
alectinib for relapsed/refractory alk nsclc
-
1:17
dr. xia on the frontline treatment landscape of alk-positive nsclc
-
1:12
dr. christina baik on alectinib in patients with alk-lung cancer